AFMDQ Quote, Financials, Valuation and Earnings

CureVac NV has a net margin of -- compared to Affimed NV's net margin of -5832.47%. Affimed NV's return on equity of -- beat CureVac NV's return on equity of 20.55%.

Affimed NV has a consensus price target of --, signalling upside risk potential of 130858.1%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 27.96%. Given that Affimed NV has higher upside potential than CureVac NV, analysts believe Affimed NV is more attractive than CureVac NV.

Affimed NV has a beta of 1.610, which suggesting that the stock is 61.013% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.

Affimed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affimed NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Affimed NV quarterly revenues are --, which are smaller than CureVac NV quarterly revenues of $63.3M. Affimed NV's net income of -- is lower than CureVac NV's net income of $319.3M. Notably, Affimed NV's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affimed NV is 0.02x versus 11.56x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Evotec SE has a net margin of -- compared to Affimed NV's net margin of -26.29%. Affimed NV's return on equity of -- beat Evotec SE's return on equity of -17.7%.

Affimed NV has a consensus price target of --, signalling upside risk potential of 130858.1%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 85.23%. Given that Affimed NV has higher upside potential than Evotec SE, analysts believe Affimed NV is more attractive than Evotec SE.

Affimed NV has a beta of 1.610, which suggesting that the stock is 61.013% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.

Affimed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affimed NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

Affimed NV quarterly revenues are --, which are smaller than Evotec SE quarterly revenues of $191.5M. Affimed NV's net income of -- is lower than Evotec SE's net income of -$50.3M. Notably, Affimed NV's price-to-earnings ratio is -- while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affimed NV is 0.02x versus 1.26x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -- compared to Affimed NV's net margin of -51538.49%. Affimed NV's return on equity of -- beat InflaRx NV's return on equity of -82.01%.

Affimed NV has a consensus price target of --, signalling upside risk potential of 130858.1%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 912.95%. Given that Affimed NV has higher upside potential than InflaRx NV, analysts believe Affimed NV is more attractive than InflaRx NV.

Affimed NV has a beta of 1.610, which suggesting that the stock is 61.013% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.

Affimed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affimed NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Affimed NV quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of $27.8K. Affimed NV's net income of -- is lower than InflaRx NV's net income of -$14.3M. Notably, Affimed NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affimed NV is 0.02x versus 342.97x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -- compared to Affimed NV's net margin of -974.45%. Affimed NV's return on equity of -- beat Immatics NV's return on equity of -25.21%.

Affimed NV has a consensus price target of --, signalling upside risk potential of 130858.1%. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 82.57%. Given that Affimed NV has higher upside potential than Immatics NV, analysts believe Affimed NV is more attractive than Immatics NV.

Affimed NV has a beta of 1.610, which suggesting that the stock is 61.013% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.

Affimed NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Affimed NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Affimed NV quarterly revenues are --, which are smaller than Immatics NV quarterly revenues of $6.1M. Affimed NV's net income of -- is lower than Immatics NV's net income of -$59.1M. Notably, Affimed NV's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Affimed NV is 0.02x versus 13.72x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.